- 4Q EARNINGS: Is 2015 Lilly's turning point?
- 3Q EARNINGS: Lilly looks to future as revenue falls
- 3Q EARNINGS: Tecfidera sales soar, but PML death hits Biogen
- Q4 EARNINGS: Merck pushes pipeline as competition, currency hit revenue
COMMENT Other Informa Comment
- INTERVIEW: Actavis CEO Saunders staying put as Allergan deal nears close
- PROFILE: Tomas Salmonson, chair of the EMA's CHMP, on European collaboration, being a teenage lifeguard, and Persian rugs
JOB OF THE WEEK Promote your job vacancy